The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a ...

SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable ...

The next-generation radiopharmaceutical ABD-147 was previously granted FDA fast track designation in extensive-stage small ...

If you're a young person (or a parent of one), you may be thinking some big thoughts about your future. Am I going to go to ...

Abdera Therapeutics Inc.’s ABD-147 has been granted U.S. orphan drug designation for the treatment of neuroendocrine carcinoma. ABD-147 is a next-generation precision radiopharmaceutical biologic ...

A woman from the Greek city of Abdera died from a cancer of the chest; a man with throat cancer survived after his doctor burned away the tumour. The word cancer comes from the same era.

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Abdera Therapeutics’ ABD-147, a treatment aimed at neuroendocrine carcinoma. The biologic therapy is ...

Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable, precision radiopharmaceuticals for cancer, today ...